Characteristics | Total (N = 22) |
---|---|
HCV genotype (%) | |
1a | 13 (59.1) |
1b | 2 (9.1) |
2 | 1 (4.5) |
3 | 6 (27.3) |
Detection HCV viral load (IU/mL) | 8.9 × 105 (2.4 × 105—5.9 × 106) |
HCV viremia detection interval (%) | |
Week 1 | 17 (77.3) |
Week 2 | 3 (13.6) |
Week 3 | 2 (9.1) |
Time to start DAA therapy (days) | 41.5 (31.0–54.5) |
DAA therapy started (%) | 22 (100) |
DAA therapy (%) | |
Sofosbuvir/velpatasvir | 10 (45.5) |
Glecaprevir/pibrentasvir | 9 (40.9) |
Ledipasvir/sofosbuvir | 2 (9.1) |
Elbasvir/grazoprevir | 1 (4.5) |
SVR4 (%) | 21 (95.5) |
SVR12 (%) | 21 (95.5)* |
Adverse events (%) | 0 (0) |
Graft failure (%) | 0 (0) |